Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtre
1.
Asian Journal of Andrology ; (6): 432-437, 2018.
Article Dans Anglais | WPRIM | ID: wpr-1009609

Résumé

The prognostic significance of initial prostate-specific antigen (PSA) level for metastatic prostate cancer remains uncertain. We investigated the differences in prognosis and response to hormonal therapies of metastatic prostate cancer patients according to initial PSA levels. We analyzed 184 patients diagnosed with metastatic prostate cancer and divided them into three PSA level groups as follows: low (<100 ng ml-1), intermediate (100-999 ng ml-1), and high (≥1000 ng ml-1). All patients received androgen deprivation therapy (ADT) immediately. We investigated PSA progression-free survival (PFS) for first-line ADT and overall survival (OS) within each of the three groups. Furthermore, we analyzed response to antiandrogen withdrawal (AW) and alternative antiandrogen (AA) therapies after development of castration-resistant prostate cancer (CRPC). No significant differences in OS were observed among the three groups (P = 0.654). Patients with high PSA levels had significantly short PFS for first-line ADT (P = 0.037). Conversely, patients in the high PSA level group had significantly longer PFS when treated with AW than those in the low PSA level group (P = 0.047). Furthermore, patients with high PSA levels had significantly longer PFS when provided with AA therapy (P = 0.049). PSA responders to AW and AA therapies had significantly longer survival after CRPC development than nonresponders (P = 0.011 and P < 0.001, respectively). Thus, extremely high PSA level predicted favorable response to vintage sequential ADT and AW. The current data suggest a novel aspect of extremely high PSA value as a favorable prognostic marker after development of CRPC.


Sujets)
Sujet âgé , Sujet âgé de 80 ans ou plus , Humains , Mâle , Adulte d'âge moyen , Antagonistes des androgènes/usage thérapeutique , Évolution de la maladie , Pronostic , Survie sans progression , Antigène spécifique de la prostate/sang , Tumeurs de la prostate/mortalité , Résultat thérapeutique
2.
Korean Journal of Urology ; : 205-211, 2015.
Article Dans Anglais | WPRIM | ID: wpr-60933

Résumé

PURPOSE: Single-agent interferon (IFN) is no longer regarded as a standard option for first-line systemic treatment of metastatic renal cell carcinoma (RCC) in Western countries. However, some patients with favorable-risk RCC may still achieve complete and long-lasting remission in response to IFN treatment. The present study compared favorable-risk Japanese patients with metastatic RCC Japanese patients who had been treated with IFN or tyrosine kinase inhibitor (TKI) therapy as a first-line systemic therapy. MATERIALS AND METHODS: From 1995 to 2014, a total of 48 patients with favorable risk as defined by the Memorial Sloan Kettering Cancer Center criteria who did not receive adjuvant systemic therapy were retrospectively enrolled in this study. We assessed the tumor response rate, progression-free survival (PFS), and overall survival (OS). RESULTS: The objective response rate for first-line therapy was 29% in the IFN group and 47% in the TKI group, but this difference did not reach the level of statistical significance. Median OS for IFN and TKI was 71 and 47 months, respectively (p=0.014). Median first-line PFS for IFN and TKI was 20 and 16 months, respectively (no significant difference). First-line IFN therapy did not prove inferior to TKI therapy in terms of OS according to metastatic sites. CONCLUSIONS: IFN is associated with a survival benefit in Japanese patients with favorable-risk metastatic RCC in the era of targeted therapy. Further prospective study is needed.


Sujets)
Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Antinéoplasiques/usage thérapeutique , Néphrocarcinome/traitement médicamenteux , Survie sans rechute , Interférons/usage thérapeutique , Japon , Tumeurs du rein/traitement médicamenteux , Métastase tumorale/traitement médicamenteux , Inhibiteurs de protéines kinases/usage thérapeutique , Protein-tyrosine kinases/antagonistes et inhibiteurs , Études rétrospectives , Facteurs de risque , Résultat thérapeutique
3.
Asian Journal of Andrology ; (6): 299-307, 2009.
Article Dans Anglais | WPRIM | ID: wpr-284686

Résumé

Androgens play a central role in prostate cancer pathogenesis, and hence most of the patients respond to androgen deprivation therapies. However, patients tend to relapse with aggressive prostate cancer, which has been termed as hormone refractory. To identify the proteins that mediate progression to the hormone-refractory state, we used protein-chip technology for mass profiling of patients' sera. This study included 16 patients with metastatic hormone-refractory prostate cancer who were initially treated with androgen deprivation therapy. Serum samples were collected from each patient at five time points: point A, pre-treatment; point B, at the nadir of the prostate-specific antigen (PSA) level; point C, PSA failure; point D, the early hormone-refractory phase; and point E, the late hormone-refractory phase. Using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry, we performed protein mass profiling of the patients' sera and identified a 6 640-Da peak that increased with disease progression. Target proteins were partially purified, and by amino acid sequencing the peak was identified as a fragment of apolipoprotein C-I (ApoC-I). Serum ApoC-I protein levels increased with disease progression. On immunohistochemical analysis, the ApoC-I protein was found localized to the cytoplasm of the hormone-refractory cancer cells. In this study, we showed an increase in serum ApoC-I protein levels in prostate cancer patients during their progression to the hormone-refractory state, which suggests that ApoC-I protein is related to progression of prostate cancer. However, as the exact role of ApoC-I in prostate cancer pathogenesis is unclear, further research is required.


Sujets)
Sujet âgé , Humains , Mâle , Adulte d'âge moyen , Séquence d'acides aminés , Antinéoplasiques hormonaux , Utilisations thérapeutiques , Apolipoprotéine C-I , Sang , Technique de Western , Lignée cellulaire , Évolution de la maladie , Résistance aux médicaments antinéoplasiques , Immunohistochimie , Données de séquences moléculaires , Pronostic , Tumeurs de la prostate , Traitement médicamenteux , Métabolisme , Analyse par réseau de protéines , Spectrométrie de masse MALDI
4.
Asian Journal of Andrology ; (6): 111-115, 2002.
Article Dans Anglais | WPRIM | ID: wpr-284062

Résumé

<p><b>AIM</b>To evaluate the occurrence and prevalence of microdeletions in the gamma chromosome of patients with azoospermia.</p><p><b>METHODS</b>DNA from 29 men with idiopathic azoospermia was screened by polymerase chain reaction (PCR) analysis with a set of gamma chromosome specific sequence-tagged sites (STSs) to determine microdeletions in the gamma chromosome.</p><p><b>RESULTS</b>Deletions in the DAZ (deleted in azoospermia) loci sgamma254 and sgamma255 were found in three patients with idiopathic azoospermia, resulting in an estimated frequency of deletions of 10.7% in idiopathic azoospermia men.</p><p><b>CONCLUSION</b>We conclude that PCR analysis is useful for the diagnosis of microdeletions in the Y chromosome, which is important when deciding the suitability of a patient for assisted reproductive technology such as testicular sperm extracion-intracytoplasmic sperm injection (TESE-ICSI).</p>


Sujets)
Adulte , Humains , Mâle , Séquence nucléotidique , Chromosomes Y humains , Amorces ADN , Euchromatine , Génétique , Hormone folliculostimulante , Sang , Hétérochromatine , Génétique , Hormone lutéinisante , Sang , Oligospermie , Sang , Génétique , Réaction de polymérisation en chaîne , Prolactine , Sang , Délétion de séquence , Génétique , Sites étiquetés par des séquences , Testostérone , Sang
5.
Asian Journal of Andrology ; (6): 123-129, 2002.
Article Dans Anglais | WPRIM | ID: wpr-284060

Résumé

<p><b>AIM</b>The metastatic ability of a Dunning R-3327 rat prostate cancer subline (AT6.3) was suppressed by the introduction of human chromosome 10, when these hybrid cancer cells were injected subcutaneously into nude mice (Nihei et al., Genes Chromosomes Cancer 14:112-119, 1995). The present study was undertaken to clarify which step of metastasis was suppressed in the human chromosome 10-containing microcell hybrids (AT 6.3-10 clones).</p><p><b>METHODS</b>Gelatin zymography, an in vitro invasion assay using a Boyden chamber and an intravenous metastasis assay involving the injection of hybrid cells into nude mice were performed.</p><p><b>RESULTS</b>Gelatin zymography revealed that AT6.3-10 microcell hybrid clones expressed the 72 kD type IV collagenase (MMP-2) at an almost equal level as control microcell hybrid clones. Both the invasiveness as measured by the invasion assay and the number of lung metastases as measured by the intravenous metastasis assay of AT6.3-10 hybrid clones were significantly less than those of the AT6.3 parental clone.</p><p><b>CONCLUSION</b>The human chromosome 10 suppresses both the local invasion and the metastatic process after entry into the blood circulation of rat prostate cancer. This decrease in local-invasive ability does not seem to require a decrease in MMP-2 activity.</p>


Sujets)
Animaux , Humains , Mâle , Souris , Rats , Animal génétiquement modifié , Division cellulaire , Chromosomes humains de la paire 10 , Gélatine , Souris de lignée BALB C , Souris nude , Invasion tumorale , Métastase tumorale , Génétique , Tumeurs de la prostate , Génétique , Anatomopathologie , Tumeurs cutanées , Génétique , Anatomopathologie , Cellules cancéreuses en culture
6.
Asian Journal of Andrology ; (6): 131-136, 2002.
Article Dans Anglais | WPRIM | ID: wpr-284059

Résumé

<p><b>AIM</b>Chromosome 13 is one of the most frequently altered chromosomes in prostate cancer. The present study was undertaken to examine the role of human chromosome 13 in the progression of prostate cancer.</p><p><b>METHODS</b>Human chromosome 13 was introduced into highly metastatic rat prostate cancer cells via microcell-mediated chromosome transfer.</p><p><b>RESULTS</b>Microcell hybrid clones containing human chromosome 13 showed suppression of metastasis to the lung without any suppression of tumorigenicity, except for one clone, which contained the smallest sized human chromosome 13 and did not show any suppression on lung metastasis. Expression of two known tumor suppressor genes, BRCA2 and RB1, which map to chromosome 13, was examined by reverse transcription- polymerase chain reaction analysis. BRCA2 was expressed only in the metastasis-suppressed microcell-hybrid clones, whereas RB1 was expressed in all clones.</p><p><b>CONCLUSION</b>Human chromosome 13 contains metastasis suppressor gene(s) for prostate cancer derived from rat. Furthermore, the RB1 gene is unlikely to be involved in the suppression of metastasis evident in this system.</p>


Sujets)
Animaux , Humains , Mâle , Rats , Animal génétiquement modifié , Division cellulaire , Génétique , Aberrations des chromosomes , Cartographie chromosomique , Chromosomes humains de la paire 13 , Évolution de la maladie , Marqueurs génétiques , Hybridation fluorescente in situ , Cinétique , Métastase tumorale , Tumeurs de la prostate , Génétique , Anatomopathologie , Génétique
SÉLECTION CITATIONS
Détails de la recherche